Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Gong

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Global Public Health|February 1, 2017
KT&G: From Korean monopoly to 'a global name in the tobacco industry'Kelley Lee, Lucy Gong, Jappe Eckhardt, et al.
The Journal of Biological Chemistry|December 17, 2008
A binding domain on mesothelin for CA125/MUC16Osamu Kaneko, Lucy Gong, Jingli Zhang, et al.
Diabetes Care|June 7, 2008
Association between parental history of type 2 diabetes and glycemic control in urban African AmericansLucy Gong, Wen Hong Linda Kao, Frederick L Brancati, et al.
Analytical Chemistry|May 17, 2012
Spectrophotometric titration of bimetallic metal cation binding in polyamido(amine) dendrimer templatesKatherine A Marvin, Justin A Johnson, Stacia E Rodenbusch, et al.
Oral Oncology|July 2, 2011
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristicsSarah M Russell, Melissa G Lechner, Lucy Gong, et al.
Blood|October 26, 2021
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLLTanya Siddiqi, Jacob D Soumerai, Kathleen A Dorritie, et al.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Global Public Health|February 1, 2017
KT&G: From Korean monopoly to 'a global name in the tobacco industry'Kelley Lee, Lucy Gong, Jappe Eckhardt, et al.
The Journal of Biological Chemistry|December 17, 2008
A binding domain on mesothelin for CA125/MUC16Osamu Kaneko, Lucy Gong, Jingli Zhang, et al.
Diabetes Care|June 7, 2008
Association between parental history of type 2 diabetes and glycemic control in urban African AmericansLucy Gong, Wen Hong Linda Kao, Frederick L Brancati, et al.
Analytical Chemistry|May 17, 2012
Spectrophotometric titration of bimetallic metal cation binding in polyamido(amine) dendrimer templatesKatherine A Marvin, Justin A Johnson, Stacia E Rodenbusch, et al.
Oral Oncology|July 2, 2011
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristicsSarah M Russell, Melissa G Lechner, Lucy Gong, et al.
Blood|October 26, 2021
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLLTanya Siddiqi, Jacob D Soumerai, Kathleen A Dorritie, et al.
The Lancet. Oncology|April 7, 2016
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialAnas Younes, Jesus G Berdeja, Manish R Patel, et al.
Pageof 1